Baxter may stay out of Heparin business

Apr 25, 2008

The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

Baxter recalled vials of the drug two months ago after reports of allergic reactions. The U.S. Food and Drug Administration said the drug may have been intentionally contaminated with an animal-like substance to increase supplier profits.

The drug generates $30 million of Baxter's more than $11 billion in annual sales, the Chicago Tribune said Thursday. The newspaper said Wall Street analysts asked Chairman and Chief Executive Robert Parkinson last week if was worth the legal risks to remain in the heparin business.

"We haven't made a decision whether or not we are going to re-enter (the market) with heparin," Parkinson said.

Copyright 2008 by United Press International

Explore further: Expression of privilege in vaccine refusal

add to favorites email to friend print save as pdf

Related Stories

Animals first flex their muscles

5 hours ago

An unusual new fossil discovery of one of the earliest animals on earth may also provide the oldest evidence of muscle tissue – the bundles of cells that make movement in animals possible.

What lit up the universe?

17 minutes ago

New research from UCL shows we will soon uncover the origin of the ultraviolet light that bathes the cosmos, helping scientists understand how galaxies were built.

Introducing the multi-tasking nanoparticle

8 hours ago

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. Built on an easy-to-make polymer, these particles ...

Recommended for you

Expression of privilege in vaccine refusal

13 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments : 0